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40 word summary: 
In this study, we show NK cell degranulation and IFN-γ secretion in response to recombinant 
Ebola virus glycoprotein and post-vaccination sera from healthy volunteers vaccinated with 
the novel 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (EBOVAC 
consortium, EU Innovative Medicines Initiative).  
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Abstract 
Background 
Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute 
to vaccine-induced protection against viral infections. Fc-mediated function of anti-Ebola 
glycoprotein antibodies suggest that Fc-dependent activation of effector cells, including NK 
cells, could play a role in vaccination against Ebola virus disease.   
Methods 
We analysed the effect of anti-Ebola glycoprotein antibody in the serum of U.K.-based 
volunteers vaccinated with the novel 2-dose heterologous Adenovirus type 26.ZEBOV, 
Modified Vaccinia Ankara-BN-Filo vaccine regimen, on primary human NK cell activation.  
Results 
We demonstrate primary human NK cell CD107a and IFN-γ expression, combined with 
downregulation of CD16, in response to recombinant Ebola virus glycoprotein and post-
vaccine dose 1 and dose 2 sera. These responses varied significantly with vaccine regimen 
and NK cell activation was found to correlate with anti-glycoprotein antibody concentration. 
We also reveal an impact of NK cell differentiation phenotype on antibody-dependent NK cell 
activation, with highly differentiated CD56dimCD57+ NK cells being the most responsive.  
Conclusions 
This study thus highlights the dual importance of vaccine-induced antibody concentration and 
NK cell differentiation status in promoting Fc-mediated activation of NK cells after vaccination, 
raising a potential role for antibody-mediated NK cell activation in vaccine-induced immune 
responses. 
 
Keywords: antibody, Ebola, vaccine, natural killer cell.  
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Background 
Determining correlates of protection for Ebola vaccines has proved difficult and ambiguous 
[1]. Anti-Ebola antibodies possess strong neutralising capacity [2, 3], moreover, antibodies 
with limited neutralising activity were protective in animal models and human in vitro culture 
systems suggesting that neutralisation alone presents an incomplete mechanistic picture of in 
vivo protection [3-5]. Ebola-specific antibodies induce antibody-dependent cellular cytotoxicity 
(ADCC) in human peripheral blood NK cells and NK cell lines in vitro; in light of this, Fc-
mediated function in anti-Ebola monoclonal antibody (mAb) therapy and vaccine-induced 
protection is gaining in interest [5-7]. Analysis of the primary response to the candidate Ebola 
vaccine, rVSV-ZEBOV, revealed a correlation between early NK cell activation and anti-Ebola 
antibody titre [8]. Also, protection of non-human primates against Ebola virus challenge is 
associated with a low IgG2:IgG1 antibody isotype ratio, compatible with ADCC as a major 
mechanism of protection [9]. In murine experimental filovirus vaccines, induction of anti-
glycoprotein (GP) antibodies with robust ADCC function was critical for protection [10-12]. 
Taken together, these studies suggest Fc functions of anti-Ebola antibodies potentially 
contribute to protection and may be exploited for improving vaccine and therapeutic mAb 
efficacy and as markers of vaccine-induced immunity.  
NK cells, like other innate immune effector cells, express Fc receptors (FcR) on their surface 
allowing activation of cell-mediated antibody-dependent anti-viral functions [13]. Antibody-
dependent phagocytosis (ADP) of virus or virally-infected cells by monocytes, macrophages 
and neutrophils, and ADCC mediated by NK cells, promote the clearance of infected cells, 
reducing viral load and dissemination. NK cell ADCC is principally mediated by crosslinking of 
FcγRIIIa (CD16) by the Fc region of immunoglobulins – subclasses IgG1 and IgG3 in humans 
– which leads to phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAM) 
and downstream pathway activation. Killing proceeds by the release of lytic granules from 
activated NK cells inducing apoptosis of virally infected cells. Cross-linking of CD16 by 
antibody induces its cleavage from the NK cell surface [14-16], despite this, NK cells can move 
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on to kill multiple targets providing effective clearance of infected cells [17]. Fc functions of 
broadly neutralising antibodies have been shown to be indispensable for protection against 
influenza virus infection [18, 19], however, the role of Ebola vaccine induced antibody-
dependent NK cell functions is unknown. 
The novel Ad26.ZEBOV, MVA-BN-Filo 2-dose vaccine regimen has shown promising results 
in phase 1 and 2 studies; high levels of anti-Ebola GP specific antibody are sustained for at 
least 360 days with high neutralising activity and a strong correlation between binding and 
neutralising antibody responses [20-23]. However, vaccine regimens based on Ad26.ZEBOV 
and MVA-BN-Filo differing in order and interval between dose 1 and dose 2 induce 
substantially different serum antibody concentrations in U.K. based volunteers at both post-
dose 1 and post-dose 2 time points [21]. Therefore, the purpose of this study was to assess 
the ability of post-Ad26.ZEBOV, MVA-BN-Filo vaccination sera (of differing regimen) to 
mediate antibody-dependent NK cell function in an in vitro ADCC assay targeting immobilised 
Ebola virus GP (EBOV GP). We observe robust, antibody-dependent activation of NK cells in 
whole human peripheral blood mononuclear cell (PBMC) preparations cultured with EBOV GP 
in the presence post-Ad26.ZEBOV, MVA-BN-Filo vaccination serum. NK cell activation varied 
depending on vaccine regimen and correlated positively with antibody concentration. NK 
activity also varied between NK cell donors, consistent with differentiation phenotype 
influencing the potency of antibody-dependent NK cell responses. 
Methods 
Study participants and samples 
Eligible, healthy volunteers were recruited to take part in the EBL1001 (EBOVAC consortium) 
single-centre, randomised, placebo-controlled, observer blind Ebola vaccine trial held in 
Oxford, U.K. (ClinicalTrials.gov Identifier: NCT02313077). A further 15 volunteers were 
subsequently recruited for group 5, see Milligan et al. for additional methodology [21]. Serum 
samples from 72 donors (age range 18-50 years) were obtained for this study from non-
placebo arms (Table 1).  
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Active vaccination comprised monovalent Ad26.ZEBOV expressing the GP of the Ebola Zaire 
virus (Mayinga variant) and multivalent MVA-BN-Filo expressing the GP of the Sudan and 
Zaire Ebola viruses and Marburg virus together with Tai Forest virus nucleoprotein (Janssen 
Vaccines and Prevention B.V., The Netherlands and Bavarian Nordic, Denmark). Participants 
received vaccination schedules as follows; groups 1 and 2 received MVA-BN-Filo on day 1 
and Ad26.ZEBOV on either day 29 or 57 respectively, groups 3, 4 and 5 received 
Ad26.ZEBOV on day 1 and MVA-BN-Filo on days 29, 57 or 15 respectively. 
Additional blood samples were obtained from non-vaccinated, non-study volunteers. PBMC 
were isolated using Histopaque 1077 (Sigma-Aldrich, U.S.A) gradient centrifugation and 
cryopreserved in liquid nitrogen or used immediately. Ebola GP-specific IgG concentration 
and Ebola GP-specific pseudovirion virus neutralising antibody titres (psVNA) were 
determined previously [21] and human cytomegalovirus (HCMV) serostatus was determined 
by IgG ELISA (Demeditec, Kassel, Germany), 36% HCMV seropositive. The trial protocol and 
study documents were approved by the National Research Ethics Service (reference number 
14/SC/1408) and the LSHTM Research Ethics Committee (reference number 14383). 
In vitro culture assays 
For antibody-dependent NK cell activation assays, 10μg/ml purified EBOV GP, Mayinga 
variant (Janssen Vaccines and Prevention B.V.) was immobilised on 96-well flat-bottom tissue 
culture plates overnight at 4°C, washed, blocked with 5% FCS in RPMI 1640 supplemented 
with 100U/ml penicillin/streptomycin and 20mM L-glutamine (Gibco, ThermoFisher) and 
washed again. Fresh PBMC from a single individual donor (non-vaccinated) were washed in 
RPMI 1640 supplemented as above and counted using Countess II FL Automated Cell 
Counter (Invitrogen, ThermoFisher). PBMC were seeded (3x105/well) onto the antigen-coated 
plates together with pre or post-vaccination serum at various concentrations (with total serum 
concentration made up to 5% with FCS) and incubated for 6 hours at 37°C. Alternatively, 
cryopreserved PBMC from multiple (non-vaccinated) donors were thawed, washed and 
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seeded onto the antigen-coated plates with pooled pre or post-vaccination serum from group 
2 (regimen; MVA-BN-Filo on day 1 and Ad26.ZEBOV on day 57). 
Anti-CD107a-FITC (clone H4A3; BD Biosciences) was added to the cultures for the entire 
culture period and GolgiStop (Monensin; 1/1500 concentration; BD Biosciences) and 
GolgiPlug (Brefeldin A; 1/1000 final concentration; BD Biosciences) were added for the final 3 
hours of culture. Positive control cultures comprised the CD20 expressing human Burkitt′s 
Lymphoma cell line (RAJI; ECACC, Salisbury, U.K.) with monoclonal anti-CD20, Rituximab 
(Ritxan®; Genentech, San Francisco, USA) at varying concentrations. In all cases, cells were 
harvested into round-bottom plates by soaking and resuspension in FACS buffer (PBS, 0.5% 
FCS, 0.05% sodium azide and 2mM EDTA) for staining.  
Flow cytometry 
Cells were stained in 96-well round-bottom plates as described previously [24]. Briefly, cells 
were blocked with Fc Receptor (FcR) Blocking Reagent (Miltenyi Biotech, Germany) and 
stained with fluorophore labelled antibodies for surface markers including viability marker 
(Fixable Viability Stain 700; BD Biosciences) in FACS buffer. Cells were washed in FACS 
buffer, fixed and permeabilised using Cytofix/Cytoperm Kit (BD Biosciences). Cells were then 
stained for intracellular markers with further FcR blocking, washed again and resuspended in 
FACS buffer and acquired using a BD LSRII flow cytometer using FACSDiva software and 
analysed using FlowJo V10 (Tree Star, Oregon, U.S.A). FACS gates were set using 
unstimulated cells or FMO controls, a minimum cut off was determined as the frequency of 
responding NK cells in the presence of FCS alone [21], samples with less than 100 NK cell 
events were excluded from the analysis. 
Fluorophore-labelled antibodies used were: anti-CD3-V500 (clone UCHT1) (BD Biosciences), 
anti-CD56-BV605 (clone HCD56) and anti-IFN-γ-BV785 (clone 45.B3) (Biolegend, London, 
U.K.), anti-CD16-APC (clone CB16), anti-CD57-e450 (clone TB01) (eBiosciences) and anti-
NKG2C-PE (clone 134591) (R&D systems). Cells were acquired using FACSDiva software, 
data were analysed using FlowJo V10 (Tree Star, Oregon, U.S.A).  
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Statistics 
Statistical analysis was performed using GraphPad Prism version 7.04 (GraphPad, California, 
U.S.A.). Functional responses were compared using Wilcoxon signed-rank test or one-way 
ANOVA Friedman test with Dunn’s correction for multiple comparisons. Correlation analysis 
was performed using linear and nonlinear regression models, the p value of the correlation of 
the two variables was determined using Pearson correlation analysis. Significance levels are 
assigned as *p, 0.05, **p, 0.01, ***p, 0.001, and ****p, 0.0001 for all tests. 
Results 
Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine induced antibody-dependent NK cell 
activation in vitro. 
To assess the effect of Ad26.ZEBOV, MVA-BN-Filo induced anti-GP antibody on NK cell 
activation, whole PBMC from one non-vaccinated donor were cultured with plate bound EBOV 
GP plus pre or post-vaccination serum. Optimal serum concentrations for CD3-CD56+ NK cell 
CD107a surface expression (gating strategy shown in Figure 1a and Supplementary Figure 
1a) were established (Supplementary figure 1b). NK cell CD107a, CD16 and IFN-γ expression 
was then measured in response to 5% pre (visit 0), post-dose 1 (visit 1) or post-dose 2 (visit 
2) serum from each individual study participant (n=72) (gating strategy shown in Figure 1a-c). 
Initially, data from all five vaccination arms were combined for analysis. Significantly higher 
frequencies of CD107a+ NK cells were observed with post-dose 1 serum compared with pre-
vaccination serum and was further enhanced with post-dose 2 serum (median 2.39% post-
dose 1, 8.24% post-dose 2) (Figure 2a). CD56dim NK cell CD16 expression measured by mean 
fluorescence intensity (MFI) decreased significantly in cells cultured with post-dose 1 serum 
and there was a further decrease in cells cultured with post-dose 2 serum (median MFI 8990 
post-dose 1, 4020 post-dose 2) (Figure 2a). Frequencies of NK cells producing IFN-γ in 
response to post-dose 1 serum were low but significantly higher than in response to pre-
vaccination serum, and again, this was strongly increased with post-dose 2 serum (median 
0.28% post-dose 1, 1.17% post-dose 2) (Figure 2).  
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The effect of Ad26.ZEBOV, MVA-BN-Filo-induced anti-GP antibody on antibody-dependent 
NK cell activation was analysed according to NK cell differentiation subset (gating strategy 
shown in Supplementary Figure 1c, Supplementary Figure 1d shows the NK cell subset 
distribution for the single donor used in this assay). NK cell CD107a expression was induced 
equally in less differentiated CD56bright and more differentiated CD56dim NK cell subsets and in 
subsets further subdivided into moderately and highly differentiated CD56dimCD57- and 
CD56dimCD57+ (NKG2C- and NKG2C+) cells (Figure 2b). This was consistent with significant 
CD16 downregulation observed in all NK cell subsets (Figure 2b). Basal CD16 expression 
increased with increasing differentiation status (CD56dimCD57- < CD56dimCD57+NKG2C- < 
CD56dimCD57+NKG2C+) and CD16 expression was maintained at higher MFI post-dose 2 in 
the most differentiated subsets (Figure 2b). CD107a was induced within the CD56bright NK cell 
population in response to post-vaccination serum, however the overall contribution of this was 
less than 14% of the total expression (p=<0.0001) (Figure 2c). IFN-γ expression in response 
to post-vaccination serum was attributed to CD56dim NK cells with no increase in expression 
observed within the least differentiated CD56bright NK cell subset (Figure 2b).  
The most highly differentiated CD56dimCD57+NKG2C- and CD56dimCD57+NKG2C+ NK cell 
subsets showed the most extensive CD16 downregulation and the highest frequencies of IFN-
γ producing cells (Figure 2b). 71.2% of all the NK cells producing IFN-γ in response to post-
dose 2 serum were CD56dimCD57+ (NKG2C+/-) NK cells, with 25.5% of IFN-γ+ cells being 
CD56dimCD57+NKG2C+ (Figure 2c). Consistent with antibody-dependent activation of more 
differentiated NK cell subsets, anti-CD20 (Rituximab) and CD20-expressing RAJI cells also 
preferentially induced NK cell degranulation and IFN-γ expression in CD56dimCD57+ (NKG2C+/-
) (Supplementary Figure 2). These data suggest that EBOV GP-specific antibody induces 
antibody-dependent NK cell activation, including IFN-γ secretion, in more differentiated NK 
cell subsets. 
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Variation in antibody-dependent NK cell activation by vaccine regimen. 
The Ebola GP-specific IgG concentration in the serum samples of Ad26.ZEBOV, MVA-BN-
Filo vaccinated individuals varied depending on the vaccination regimen [21]. We therefore 
analysed the impact of vaccine regimen on antibody-dependent NK cell activation. There was 
significant upregulation of CD107a, IFN-γ and downregulation of CD16 with post-dose 2 serum 
in all groups compared with pre-vaccination serum responses, however responses differed 
significantly between study arms (Figure 3a-c).  
Groups 1 and 2 (MVA-BN-Filo followed by Ad26.ZEBOV) resulted in the strongest induction 
of CD107a and IFN-γ expression and the lowest CD16 MFI of all five groups (Figure 3a-c). 
Serum collected after MVA-BN-Filo (dose 1) did not induce NK cell activation, but significant 
induction of CD107a, IFN-γ and downregulation of CD16 was seen with post-Ad26.ZEBOV 
(dose 2) serum (when compared with both pre and post-dose 1 vaccination serum) (Figure 
3a-c, Supplementary Table 1). By contrast, in groups 3, 4 and 5 (Ad26.ZEBOV followed by 
MVA-BN-Filo) there was induction of NK cell responses to post-Ad26.ZEBOV (dose 1) serum 
that were further enhanced by post-MVA-BN-Filo (dose 2) serum (Figure 3a-c, Supplementary 
Table 1). However, earlier MVA-BN-Filo dose 2 in group 3 (day 29) and group 5 (day 15) did 
not result in further significant NK activation (by one-way ANOVA, Supplementary Table 1) 
over that with the first dose of Ad26.ZEBOV (except weak boosting of IFN-γ in group 3) and 
group 5 resulted in the weakest overall response (Figure 3a-c, Supplementary Table 1). This 
suggests that Ad26.ZEBOV as first dose induces sufficient concentrations of antibody for a 
robust NK cell response that is further increased by MVA-BN-Filo second dose, whilst MVA-
BN-Filo alone does not induce sufficient antibody (or antibody of the correct isotype or 
subclass) to mediate ADCC.  
 
Correlation of NK cell function with anti-GP antibody concentration and pseudovirion 
virus neutralising antibody titres. 
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Variation in NK cell function according to vaccine regimen is consistent with data on the effect 
of vaccine regimen on anti-GP antibody concentration [21]. Therefore, we next analysed the 
relationship between individual Ebola GP-specific IgG concentration (determined by Milligan 
et al. previously [21]) and antibody-dependent NK cell activation. With all groups combined, 
there was a significant positive correlation between post-dose 2 antibody concentration and 
frequencies of NK cell CD107a and IFN-γ and a negative correlation with CD16 MFI (Figure 
4a).  
Groups 1 and 2 (MVA-BN-Filo followed by Ad26.ZEBOV) demonstrated the highest median 
NK cell functional responses post-dose 2 (Wilcoxon paired t test CD107a+ NK cell frequency; 
group 1 vs 3; p=0.0479, group 2 vs 4; p=0.0166). However, when analysed according to 
vaccination group, only groups 3-5 (Ad26.ZEBOV followed by MVA-BN-Filo) demonstrated a 
significant correlation between post-dose 2 antibody concentration and NK cell function (Table 
2). Antibody concentration and NK cell function also correlated significantly after dose 1 when 
all groups were combined (Supplementary Figure 3a-c), however, this relationship was only 
significant for group 3 (Ad26.ZEBOV followed by MVA-BN-Filo at day 29) when analysed 
separately (Table 2). There was no correlation between antibody concentration and antibody-
dependent NK cell function at post-dose 1 and post-dose 2 in MVA-BN-Filo followed by 
Ad26.ZEBOV vaccinated individuals (groups 1 and 2) (Table 2). Therefore, in vaccine regimen 
inducing the highest post-dose 2 responses (groups 1 and 2), the association between the 
two variables is lost. 
Analysis of antibody-dependent NK cell responses and Ebola GP-specific pseudovirion virus 
neutralising antibody titres (psVNA) titres revealed a significant positive correlation across the 
entire cohort with the frequency of NK cell IFN-γ and a negative correlation with CD16 
expression, although no association was observed with CD107a expression (Figure 4b). 
Consistent with the association with anti-GP antibody concentration, we observed the 
strongest correlations between all NK cell functions and psVNA titres for groups 3 and 4 
(Ad26.ZEBOV followed by MVA-BN-Filo) (Table 3).  
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Variation in antibody-dependent NK cell function by NK cell donor. 
To analyse the effect of donor variation, PBMC from non-vaccinated donors (n=16) were 
cultured with plate bound EBOV GP and pooled pre or post-dose 2 vaccination serum samples 
from group 2 (MVA-BN-Filo followed by Ad26.ZEBOV at day 57). NK cell CD107a (14 of 16 
responding), CD16 downregulation (16 of 16 donors responding) and IFN-γ (13 of 16 donors 
responding) was induced with pooled post-dose 2 serum compared with pooled pre-
vaccination serum (Figure 5a) suggesting the majority of donors respond to Ad26.ZEBOV, 
MVA-BN-Filo vaccine-induced antibody. 
We next analysed NK cell activation in response to pooled post-dose 2 serum according to 
NK cell differentiation subset. Amongst the individuals tested, frequencies of the most highly 
differentiated CD56dimCD57+NKG2C+ NK cells varied widely (with 5 of 16 donors showing 
frequencies above 10%) with a wide range of subset frequency (Figure 5b). Overall, NK cell 
CD107a expression was apparent in all NK cell subsets, as was CD16 downregulation (Figure 
5c). IFN-γ was significantly upregulated with post-dose 2 serum in CD56dimCD57- and 
CD56dimCD57+NKG2C- subsets with the highest frequency of IFN-γ expression observed 
within the CD56dim NK cell subsets (Figure 5c). Almost half (41.0%) of total NK cell IFN-γ 
production was attributed to CD56dimCD57+ NK cells (Figure 5d). These data demonstrate that 
differences in NK cell differentiation status introduce additional inter-donor variation in NK cell 
ADCC responses. 
Discussion 
We have shown that antibodies to the Ebola virus GP induced by the Ad26.ZEBOV, MVA-BN-
Filo vaccine regimen activate robust in vitro NK cell degranulation and IFN-γ secretion on co-
culture with Ebola GP antigen. These NK cell responses are highly variable depending on 
vaccine regimen and interval and correlate with anti-GP IgG concentration and are markedly 
enriched in (although not limited to) more differentiated NK cell subsets. Varying NK cell 
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differentiation status between donors contributes to the heterogeneity of post-vaccination 
ADCC responses. 
The positive correlation between post-dose 2 antibody concentration and NK cell activation 
demonstrates a good read-out of antibody-dependent effector function. Interestingly, MVA-
BN-Filo followed by Ad26.ZEBOV vaccine regimen (groups 1 and 2), giving rise to both the 
highest numerical geometric mean Ebola GP-specific IgG concentration and median NK cell 
function did not result in significant correlations between the two factors on an individual level. 
NK cell CD107a expression did not increase further with the higher antibody concentrations 
induced by delayed second dose (day 57) compared with earlier second dose (day 29) 
suggesting sufficient antibody concentrations can be achieved with the early (day 29) dose 2 
to obtain optimal responses [21]. NK cell IFN-γ expression was higher with a later second 
dose (day 57) compared with the earlier second dose (day 29) suggesting that increasing 
levels of anti-GP antibody are associated with stronger NK cell cytokine secretion. The lack of 
correlation between antibody concentration and NK cell responses after MVA-BN-Filo followed 
by Ad26.ZEBOV regimen highlights a requirement for a two-dose vaccine regimen or primary 
vaccination with Ad26.ZEBOV to in uce robust NK cell responses. This may additionally 
reflect effects of antibody affinity maturation and isotype/subclass switching. Of note, the 
Ad26.ZEBOV followed by MVA-BN-Filo vaccine regimen are being further evaluated in phase 
2 and 3 clinical studies. 
NK cell activation after Ad26.ZEBOV, MVA-BN-Filo vaccination regimen required relatively 
high serum concentrations, similar levels of NK cell degranulation occurring with up to 40-fold 
lower concentrations of post-seasonal influenza vaccination serum [16]. Importantly, only 
antibodies binding to Ebola virus GP contributed to the response; antibodies specific for the 
nucleoprotein (contained in MVA-BN-Filo) were not assessed. Significant correlations 
between NK cell function and psVNA were also observed post-dose 2, most significantly for 
Ad26.ZEBOV, MVA-BN-Filo vaccine regimen. This is consistent with a previously reported 
direct temporal and quantitative relationship between specific IgG concentrations and 
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neutralising activity and with a subset of vaccine induced antibodies having both NK cell 
activation and virus neutralising properties [20, 22]. 
Our data highlight substantial variation in frequencies of activated NK cells subsets both within 
a single donor and between donors in response to post-vaccination antibody. Many variables 
effect NK cell ADCC function including FcR polymorphisms [25], antibody glycosylation [26] 
and cytokine mediated regulation [27]. Antibody binding epitopes can also affect the ADCC 
function of vaccine induced antibodies [3] - neutralising antibodies bind Ebola GP core 
epitopes potentially inhibiting virion cell entry whereas antibodies with Fc function bind 
epitopes on the exposed upper domains of GP presented on the surface of infected cells [6, 
28]. Ebola GP returning to the surface of the infected cell and liberation of soluble GP for 
immune complex formation could promote NK cell ADCC. However, GP shed from infected 
cells can also bind anti-GP antibodies and block, rather than facilitate their activity [29].  
HCMV has seropositivity rates of up to 60% in adults in developed countries and near 
universal in developing countries [30]. HCMV infection strongly influences NK cell function in 
response to viral antigens and promotes accumulation of NK cells expressing NKG2C with a 
mature (CD56dimCD57+) and ‘adaptive’ (FcεRγ-) phenotype [31-33] with enhanced IFN-γ 
secretion in response to antibody-coated targets [34-36]. HCMV serostatus may impact 
antibody-dependent NK cell activation after Ad26.ZEBOV, MVA-BN-Filo regimen vaccination, 
therefore, measuring NK cell function may help evaluate vaccine responses across different 
human populations.  
Future use of CD16 expressing or transfected NK cell lines for standardisation of these assays 
could potentially enable comparison across multiple vaccine studies [37]. However, NK cell 
tumour lines such as NK-92, are largely derived from pre-NK cells and do not reflect the range 
of Fc receptor expression, activation requirements or functional differentiation of primary 
human NK cells; factors important in African settings where NK cells are enriched for highly 
differentiated subsets. Alternatively, Wines et al. have described a system using soluble 
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dimeric ectodomains of human FcγRIII or FcγRII (CD32) which facilitate evaluation of antibody 
isotype specificity and binding to low and high affinity variants of these FcR [38]. 
In summary, Ad26.ZEBOV, MVA-BN-Filo vaccine-induced antibody promotes strong 
antibody-dependent NK cell activation that correlates with antibody concentration. This study 
suggests NK cells are potential mediators of immunity after Ebola vaccination where 
responses are determined by both the level of antibody and effector NK cells differentiation 
status. Antibody-dependent NK cell function may help define the effector capacity of vaccine-
induced antibodies when combined with antibody level or neutralisation assays.  
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Tables 
Table 1: Vaccination regimen of each trial arm and serum samples used in this study. MVA, 
MVA-BN-Filo; Ad26, Ad26.ZEBOV. 
  Serum samples used in this study: 
Group (number 
of participants) 
Vaccine 
schedule 
Baseline 
(Visit 0) 
Post-dose 1 
(Visit 1) 
Post-dose 2 
(Visit 2) 
1 (n=15) MVA, Ad26 Day 1 Day 29 Day 50 
2 (n=15) MVA, Ad26 Day 1 Day 57 Day 78 
3 (n=14) Ad26, MVA Day 1 Day 29 Day 50 
4 (n=14) Ad26, MVA Day 1 Day 57 Day 78 
5 (n=14) Ad26, MVA Day 1 Day 15 Day 36 
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Table 2: The correlation between NK cell CD107a, CD16 and IFN-γ expression in response 
to plate bound EBOV GP plus post-dose 1 (visit 1) and post-dose 2 (visit 2) serum and anti-
GP antibody concentration (determined previously by Milligan et al. [21]) according to vaccine 
regimen group. R2 determined by linear regression, significance defined as p < 0.05, non-
significant correlations shaded in grey. 
Visit Group 
CD107a (%) CD16 (MFI) IFN-γ (%) 
R2 (p value) R2 (p value) R2 (p value) 
1 
1 (Day 29) 0.129 (0.207) 0.00292 (0.848) 0.0214 (0.603) 
2 (Day 57) 0.00469 (0.816) 0.0193 (0.621) 0.00638 (0.777) 
3 (Day 29) 0.480 (0.006) 0.550 (0.0024) 0.553 (0.0023) 
4 (Day 57) 0.0924 (0.291) 0.312 (0.0378) 0.248 (0.070) 
5 (Day 15) 0.394 (0.0521) 0.221 (0.171) 0.397 (0.0508) 
2 
1 (Day 50) 0.0209 (0.607) 0.00775 (0.755) 0.00144 (0.893) 
2 (Day 78) 0.0639 (0.363) 0.0339 (0.511) 0.0895 (0.279) 
3 (Day 50) 0.660 (0.0004) 0.554 (0.0023) 0.531 (0.0031) 
4 (Day 78) 0.364 (0.0225) 0.612 (0.0009) 0.327 (0.0326) 
5 (Day 36) 0.859 (0.0001) 0.690 (0.0029) 0.276 (0.119) 
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Table 3: The correlation between NK cell CD107a, CD16 and IFN-γ expression in response 
to plate bound EBOV GP plus post-dose 2 (visit 2) serum and Ebola GP-specific pseudovirion 
virus neutralising antibody titres (determined previously by Milligan et al. [21]) according to 
vaccine regimen group. R2 determined by linear regression, significance defined as p < 0.05, 
non-significant correlations shaded in grey.  
Visit Group 
CD107a (%) CD16 (MFI) IFN-γ (%) 
R2 (p value) R2 (p value) R2 (p value) 
2 
1 (Day 50) 0.0001 (0.968) 0.006 (0.794) 0.425 (0.012) 
2 (Day 78) 0.063 (0.363) 0.034 (0.511) 0.089 (0.278) 
3 (Day 50) 0.446 (0.018) 0.331 (0.050) 0.352 (0.042) 
4 (Day 78) 0.485 (0.006) 0.548 (0.003) 0.503 (0.005) 
5 (Day 36) 0.182 (0.291) 0.306 (0.155) 0.380 (0.103) 
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Figure Legends 
Figure 1: Flow cytometry gating strategy for NK cell CD107a, CD16 and IFN-γ expression. 
Flow cytometry plots show CD3-CD56+ NK cell (gating strategy shown in Supplementary 
Figure 1a) CD107a (a), CD16 (b) and IFN-γ (c) expression in response to 5% pre-vaccination 
(visit 0), post-dose 1 (visit 1) and post-dose 2 (visit 2) vaccination serum and plate bound 
EBOV GP antigen. Whole PBMC from one non-vaccinated single donor were used for NK cell 
activation assays in Figures 1-4, the NK cell differentiation phenotype of the donor is shown 
in Supplementary Figure 1d. 
 
Figure 2: Antibody-dependent NK cell responses to plate bound EBOV GP after Ad26.ZEBOV, 
MVA-BN-Filo vaccination. 
The median and 95% confidence interval of NK cell CD107a, CD56dimCD16 MFI and IFN-γ  
responses to pre (visit 0), post-dose 1 (visit 1) and post-dose 2 (visit 2) vaccination serum 
sample are shown (a) – all vaccine arms combined (n=72). NK cell CD107a, CD16 and IFN-γ  
responses were analysed according to NK cell differentiation subset defined by CD56, CD57 
and NKG2C expression (gating strategy shown in Supplementary Figure 1c) (b). Each 
individual serum donor is represented by a dot with a line at the median. The proportion of 
total NK cell CD107a and IFN-γ expression (at post-dose 2) attributed to each subset is shown 
as a pie graph with each slice representing the median (c). Comparisons across vaccination 
visits and between subsets were performed using one-way ANOVA with Holm-Sidak’s test for 
multiple comparisons. ****p < 0.0001. 
 
Figure 3: Antibody-dependent NK cell activation varies with vaccine regimen. 
NK cell CD107a (a), CD56dimCD16 MFI (b) and IFN-γ (c) expression was plotted according to 
vaccine regimen (groups 1-5) for pre (visit 0), post-dose 1 (visit 1) and post-dose 2 (visit 2) 
vaccination time points, graphs show median only. Comparisons between visits within each 
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group were performed using one-way ANOVA with Dunn’s correction for multiple comparisons 
and summarised in Supplemntary Table 1.  
 
Figure 4: NK cell activation correlates with anti-GP antibody concentration and pseudovirion 
virus neutralising antibody titres. 
Post-dose 2 anti-GP antibody concentration (a) or Ebola GP-specific pseudovirion virus 
neutralising antibody titres (psVNA) (b), (determined previously by Milligan et al. [21]) was 
correlated with post-dose 2 NK cell CD107a, CD56dimCD16 MFI and IFN-γ expression, all 
vaccination groups combined. A two-phase nonlinear regression model was fitted in prism, R2 
goodness-of-fit analysis is shown, p values were determined by Pearson correlation, 
significance was defined as p < 0.05. 
 
Figure 5: NK cell activation varies with NK cell donor. 
NK cell CD107a, CD56dimCD16 MFI and IFN-γ expression (multiple non-vaccinated donors; 
n=16) in response to 5% pooled pre and post-dose 2 vaccination serum (group 2) and plate 
bound EBOV GP (a). The NK cell subset frequency distribution is shown for each donor (b). 
The NK cell CD107a, CD16 and IFN-γ responses were also analysed according to NK cell 
differentiation subset (c) and the proportion of total NK cell IFN-γ expression (at post-dose 2) 
attributed to each subset is shown as a pie graph with each slice representing the median (d). 
Graphs show before and after plots with a line connecting each donor or one dot per donor 
with a line representing the median. Comparisons between pre and post-vaccination serum 
responses were performed using Wilcoxon signed-rank test and between subsets using one-
way ANOVA with Dunn’s correction for multiple comparisons. *p < 0.05, **p < 0.01, ****p < 
0.0001. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz657/5672569 by London School of H
ygiene & Tropical M
edicine user on 07 January 2020
